Oragenics Regains Full NYSE American Compliance, Company Resolves Stockholder Equity Deficiency October 21, 2025
Oragenics Announces Strategic Partnership with Receptor.AI to Accelerate Pipeline Development October 7, 2025
Oragenics Selects Southern Star Research as Clinical Research Organization for ONP-002 Phase IIa Trial July 31, 2025
Oragenics, Inc. Announces U.S.-Based Drug Manufacturing Agreement to Support ONP-002 Clinical Development July 16, 2025
Oragenics, Inc. Announces Pricing of Public Offering of up to $20 Million of Preferred Stock and Warrants July 1, 2025
Oragenics to Present at 2025 BIO International Convention and Attend 42nd Annual National Neurotrauma Society Symposium June 10, 2025
Oragenics, Inc. Announces Approval to Initiate Phase II Concussion Drug Trial in Australia May 13, 2025
